|Bid||64.01 x 100|
|Ask||65.00 x 300|
|Day's range||64.01 - 66.23|
|52-week range||51.05 - 135.59|
|PE ratio (TTM)||N/A|
|Earnings date||2 May 2018 - 7 May 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||113.71|
Intercept (ICPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Intercept (ICPT) missed on both earnings and revenues in the fourth quarter as Ocaliva sales were drab due to safety issues of the drug.
The New York-based company said it had a loss of $4.43 per share. The results missed Wall Street expectations. The average estimate of 10 analysts surveyed by Zacks Investment Research was for a loss of ...
Intercept (ICPT) initiates a randomized phase III trial, REVERSE, on obeticholic acid in subjects with compensated cirrhosis due to non-alcoholic steatohepatitis.
The recent weakness in lead drug Ocaliva sales due to safety issues may mar Intercept's (ICPT) performance in the fourth quarter.
Intercept, Seattle Genetics and Corcept rose above the froth Thursday — popping on key drug, merger and earnings news.
NEW YORK, Jan. 19, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Basic Energy Services, Inc. (NYSE:BAS), Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT), Natus Medical Incorporated (NASDAQ:BABY), Surmodics, Inc. (NASDAQ:SRDX), EnviroStarm, Inc. (NYSE:EVI), and Nicolet Bankshares Inc. (NASDAQ:NCBS), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.
In spite of concerns regarding lead drug Ocaliva, Intercept's 46% plunge last year might offer an intriguing buying opportunity.
Intercept (ICPT) had a tough time in 2017 after news of death were out related to lead drug's Ocaliva's dosing. We do not expect a phenomenal revival in 2018 either.
Intercept will push a Phase 3 study of its liver disease drug, Ocaliva, in cirrhotic nonalcoholic steatohepatitis into the first quarter, an analyst said Thursday.
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Intercept Pharmaceuticals, Inc. of the November 27, 2017 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Healthcare stocks are some of the most intriguing long-term stocks to buy. Picking up these stars now could end up being very profit-friendly.
Pomerantz LLP announces that a class action lawsuit has been filed against Intercept Pharmaceuticals, Inc. and certain of its officers. The class action, filed in United States District Court, Southern District of New York, and docketed under 17-cv-07371, is on behalf of a class consisting of investors who purchased or otherwise acquired Intercept securities, seeking to recover compensable damages ...
Bragar Eagel & Squire, P.C. announces that a class action lawsuit has been filed in the U.S. District Court for the Southern District of New York on behalf of all persons or entities who purchased or otherwise acquired Intercept Pharmaceuticals, Inc.
A change in revenue recognition boosts Intercept's third-quarter results, but all eyes are on its phase 3 Regenerate trial.
The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Intercept Pharmaceuticals, Inc. who purchased shares between May 31, 2016 and September 20, 2017.
Intercept Pharmaceuticals popped to a two-week high Wednesday after it topped Wall Street's third-quarter expectations.
The New York-based company said it had a loss of $2.89 per share. The results surpassed Wall Street expectations. The average estimate of nine analysts surveyed by Zacks Investment Research was for a loss ...
The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of investors who purchased Intercept Pharmaceuticals, Inc.